All In Biotech

Drug Trial Radar · NCT05547906

Evaluation of the Safety and Efficacy of ASCA101 in Patients With Advanced Solid Tumors

An Open-label, Dose-escalation, Dose-expansion, Phase 1 Study to Evaluate the Tolerability, Safety, Pharmacokinetics/Pharmacodynamics, and Antitumor Effect of ASCA101 in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Mar 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

18

Actual

Start

Nov 8, 2021

Primary completion

Feb 29, 2024

Study completion Feb 29, 2024

Sponsor

Lead sponsor
MetaFinesIndustry
Sponsor type
Industry
First posted
Sep 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, open-label, dose escalation Phase 1 study. The purpose of this study is to evaluate the following objectives in patients with advanced solid tumors after failure of standard of care.

Conditions

  • Solid Tumor

Interventions

  • ASCA101Drug

    IV infusion Twice a Week, 8 times per each Cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum tolerated dose(MTD)Time frame: 4weeks

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • California Research Institute

    Los Angeles, California

  • Seoul national university bundang hospital

    Seongnam-si, Gyeonggi-do, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.